Spectrum’s Delay In Starting Confirmatory Trial Of Poziotinib Troubles US FDA

 
• By Brenda Sandburg
  
Benefits_risks
FDA panel to weigh the benefits and risks of Spectrum's lung cancer drug poziotinib • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers